Consistently, the TGF-β signaling pathway has been successfully targeted in hepatocellular carcinoma cells and triple-negative breast cancer cells with a small molecular inhibitor (LY2157299) or with a humanized neutralizing antibody against TGF-β receptor type II [35, 36]. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.